Abstract
The nuclear transcription factor-κB (NF-κB) and free radicals are known to be involved in apoptosis. We studied the effects of a series of di-aryl-substituted pyrazole NF-κB inhibitors including tepoxalin on tumor necrosis factor α (TNFα)-induced apoptosis in murine fibrosarcoma WEHI 164 cells. We found that potent inhibitors of NF-κB were also effective in attenuating apoptosis. WEHI 164 cells that had been dually treated with tepoxalin and the antioxidant pyrrolidine dithiocarbamate (PDTC) were significantly protected from TNFα-induced killing. To study the role of free radicals in mediating TNFα-induced apoptosis, stable WEHI 164 cells overexpressing Bcl-2, an antioxidant protein, were generated. These cells were protected from TNFα-induced apoptosis and neither tepoxalin nor PDTC provided further significant protection. These results suggest that Bcl-2, PDTC, and tepoxalin may attenuate apoptosis in this system by affecting the same signaling pathway or converging pathways. Because tepoxalin suppresses the release of free radicals, PDTC scavenges free radicals and Bcl-2 is an antioxidant protein, free radicals are among the key mediators of this TNF-induced killing event. Tepoxalin and antioxidants may be useful in developing new therapeutics for treating neurodegenerative diseases, autoimmune deficiency syndrome, and ischemia-reperfusion injuries.
Footnotes
-
Send reprint requests to: Dr. Daniel H.S. Lee, Rm 345, Research Building, The R.W. Johnson Pharmaceutical Research Institute, McKean & Welsh Roads, Spring House, PA 19477-0776. E-mail:dlee{at}prius.jnj.com
- Abbreviations:
- NF-κB
- nuclear factor-κB
- TNFα
- tumor necrosis factor α
- PDTC
- pyrrolidine dithiocarbamate
- CO
- cyclooxygenase
- LO
- lipoxygenase
- PO
- peroxidase
- PGHS1
- prostaglandin synthase 1
- MTT
- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- ELISA
- enzyme-linked immunosorbent assay
- FCS
- fetal calf serum
- Received September 10, 1998.
- Accepted January 8, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|